Hepatitis C pharmacogenetics: state of the art in 2010.
In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. nafdhal@caregroup.harvard.edu
Nezam H
NH
Afdhal
John G
JG
McHutchison
Stefan
S
Zeuzem
Alessandra
A
Mangia
Jean-Michel
JM
Pawlotsky
Jeffrey S
JS
Murray
Kevin V
KV
Shianna
Yasuhito
Y
Tanaka
David L
DL
Thomas
David R
DR
Booth
David B
DB
Goldstein
D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000191:economics / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D010597:Pharmacogenetics / Q000331:legislation & jurisprudence; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load; D000095022:Interferon Lambda
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a